Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed NSCLC * T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT * Planned to undergo resection after chemo-IO according to routine treatment guidelines * Willing and able to provide written informed consent for the trial * Above 18 years of age on day of signing informed consent * Have measurable disease based on RECIST 1.1 * Have a ECOG performance status of 0-1, and are considered operable based on pulmonary function test and/or exercise testing Exclusion Criteria: * Patients deemed inoperable * Patients who have received a splenectomy * Patients who have received any vaccination within 14 days of enrollment * Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid \>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. * Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.